HCW Biologics maintains momentum toward IND application for solid tumor study
HCWB•HCW Biologics said its IND application for a clinical study evaluating its lead T-cell engager in solid tumors is on track to be filed in the first half of 2027.
1. Application timeline
HCW Biologics said it is maintaining momentum toward completing an IND application for a clinical study of its lead T-cell engager in solid tumors, with filing on track for the first half of 2027.
